register free | resend password


Entheon Biomedical to Begin Trading on the Frankfurt Exchange

ID: 1562624
recent pressrelease next pressrelease

(businesspress24) - Vancouver, BC - November 26, 2020 - Entheon Biomedical Corp. (Entheon or the Company) (CSE: ENBI) (FSE: 1XU1), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce that its shares have commenced trading on the Frankfurt Stock Exchange under the symbol 1XU1.

The Frankfurt Stock Exchange is the world''s tenth largest organized exchange-trading market in terms of turnover and dealings in securities. Over 3,000 international companies are listed on the Frankfurt Exchange.

"We are pleased to have Entheon listed on the FSE in addition to the CSE. This presence will expand accessibility to a larger, more global community of potential institutional and retail investors, with the potential of expanding our shareholder base while increasing Entheons liquidity, said Timothy Ko, CEO of Entheon. By trading on the FSE, the Company has extended its trading window by an additional six hours.

The Company''s common shares will continue to trade on the Canadian Securities Exchange under the symbol "ENBI".

About Entheon Biomedical Corp.

Entheon is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective Dimethyltryptamine based psychedelic therapeutic products (DMT Products) for the purposes of treating addiction and substance use disorders. Subject to obtaining all requisite regulatory approvals and permits, Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics and licensed psychiatrists in the United States, certain countries in the European Union and throughout Canada.

For more information, please contact the Company at:

Entheon Biomedical Corp.
Timothy Ko
Telephone: +1 (604) 562-3932
info(at)entheonbiomedical.com
https://entheonbiomedical.com/

For media inquiries, please contact Crystal Quast at:

Bullseye Corporate


Crystal Quast
Telephone: +1 (647) 529-6364
Quast(at)BullseyeCorporate.com

Cautionary Note on Forward Looking Information: This news release contains forwardlooking statements and forwardlooking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forwardlooking statements or information. More particularly and without limitation, this news release contains forwardlooking statements and information relating to the trading of the Companys shares on the Frankfurt Stock Exchange and other matters. The forwardlooking statements and information are based on certain key expectations and assumptions made by management of the Company. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forwardlooking statements and information since no assurance can be given that they will prove to be correct.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forwardlooking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the trading of the Company''s securities on the Frankfurt Stock Exchange and the Company''s ability to maintain regulatory and exchange approvals. Accordingly, readers should not place undue reliance on the forwardlooking statements and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive. The forwardlooking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forwardlooking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.

Neither the CSE nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.




More information:
http://



Keywords (optional):



Company information / Profile:

PressRelease by

Requests:





PressContact / Agency:



published by: irw
print pressrelease  send to a friend  

Date: 11/26/2020 - 14:32
Language: English
News-ID 1562624
Character count: 4849
Kontakt-Informationen:
Firma: Entheon Biomedical Corp.
Ansprechpartner: Feedback to businesspress24.com about Pressrelease-id:
Stadt: Wien
Telefon:

Meldungsart:
Versandart:
Freigabedatum:
Comments:



Number of hits: 398

Linking-Tips:



Direct Link to this PressRelease:






We would appreciate a link in your News-, Press- or Partner-Site.

Comments on this PressRelease






All members: 9 438
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 79


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.